14 Best Mid-Cap Growth Stocks to Buy Right Now

Page 8 of 13

6. Halozyme Therapeutics Inc. (NASDAQ:HALO)

Number of Hedge Fund Holders: 42

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the best mid-cap growth stocks to buy right now. On January 8, TD Cowen raised its price target on Halozyme to $90 from $79 and kept a Buy rating. Ahead of Q4 2025 earnings, the firm adjusted price targets within the diagnostic tools group and noted that investor sentiment is beginning to shift positively. 2026 guidance will be key for investors looking to position themselves for a sector-wide recovery.

On the same day, Takeda and Halozyme Therapeutics announced a global collaboration and exclusive license agreement. The partnership grants Takeda exclusive access to Halozyme’s proprietary ENHANZE drug-delivery technology for use with vedolizumab, which is marketed globally as ENTYVIO. Vedolizumab is a biologic therapy approved for treating adults with moderately to severely active ulcerative colitis and Crohn’s disease, with total global exposure surpassing one million patient years to date.

The agreement was finalized in December 2025 and provides Takeda with Halozyme Therapeutics Inc.’s (NASDAQ:HALO) recombinant human hyaluronidase PH20 enzyme to facilitate the subcutaneous delivery of vedolizumab. By integrating this commercially validated technology, Takeda aims to offer patients greater treatment flexibility and reduced time spent on therapy management.

Halozyme Therapeutics Inc. (NASDAQ:HALO) is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and devices in the US and internationally.

Page 8 of 13